Gadoteridol
CAS: 120066-54-8
Ref. 3D-VEA06654
| 25mg | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued | ||
| 250mg | Discontinued | ||
| 500mg | Discontinued |
Product Information
- Gadolinium, [10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-N1,N4,N7,N10,O1,O4,O7,O10]-
- 1,4,7,10-Tetraazacyclododecane, gadolinium deriv.
- gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate
- [10-[2-(Hydroxy-κO)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-κN1,κN4,κN7,κN10,κO1,κO4,κO7]gadolinium
- Gadolinium, [10-[2-(hydroxy-κO)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-κN1,κN4,κN7,κN10,κO1,κO4,κO7]-
- 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-(2-hydroxypropyl)-, gadolinium complex
Gadoteridol is a gadolinium chelate that has been used as a contrast agent for magnetic resonance imaging (MRI) and computed tomography (CT). Gadoteridol can be injected intravenously or administered as an intra-arterial infusion. Gadoteridol is not absorbed from the gastrointestinal tract but can be taken orally if it is encapsulated in dextran sulfate. The water permeability of gadoteridol is greater than that of gadolinium, which allows it to cross the blood-brain barrier more easily. Gadoteridol binds to activated macrophages, lymphocytes, and neutrophils. It has been shown that gadolinium accumulates in liver tissue and causes lesions in rats given doses high enough to cause liver damage. Gadolinium accumulation may also occur in humans after repeated administration of this drug.
Gadoteridol has been shown to have biological properties including experimental model studies on animals, diagnosis of disease activity by MRI,
